2026 American Academy of Neurology Abstract Website

Objective:

We aimed to identify the frequency and the type of movement disorders in the published literature in MOGAD patients.

Background:

Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are a novel spectrum of demyelinating disease. Clinical presentation of MOGAD is variable with a heterogenous manifestations as optic neuritis, myelitis and encephalopathy however, movement disorders is still underreported.

Design/Methods:

An extensive literature review through PubMed and google scholar was done according to PRISMA guidelines. The following keywords were used (movement disorders, tremors, chorea, dystonia, ataxia, myoclonus, nystagmus, tonic spasms, MOGAD, Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders). Six studies were included in our analysis. The treatment used in each patient has been collected.

Results:

Twenty-four patients were included. 70.8% of the included patients were pediatric age group while 29.2% were adult. Mean age of the pediatric and adult patients respectively was 8.1 + 3.2 years and 34.1 + 16.3 years. 58.3% were Females and 41.7% males.

Gait ataxia was identified in 91.7% cases (22 patients). One patient was affected by multiple symptoms presenting intention tremor, chorea and nystagmus. No dystonia or other movement disorders were identified. IVMP was used in 23 patients (95.8%), PLEX and IVIG were used in 17 patients (70.8%). Other treatment options were rituximab in 3 patients, methotrexate in one patient and azathioprine in two patients.

Conclusions:

Movement disorders could be a significant aspect of MOGAD patient’s presentations, in particular gait ataxia. Further research addressed to identify the real prevalence of ataxia and its clinical characteristics is essential to improve understanding and identifying the best treatment strategies.